Longitude beats 'brutal' conditions as new life science fund exceeds target
This article was originally published in Scrip
After reporting in September that it raised $331.6 million of a $375 million venture capital fund, Menlo Park, California-based Longitude Capital announced on 10 October that it closed Longitude Venture Partners II with $385 million to invest in drug development and medical technology.
You may also be interested in...
Gene editing is all the rage in biotechnology these days, but Caribou Biosciences Inc. has taken a different path than its CRISPR peers by diversifying beyond therapeutics to agriculture, industrial and applied research. The company also has taken a different financing path – recently closing a $30m Series B venture capital round instead of pursuing an initial public offering.
US FDA-approved belantamab mafodotin is indicated for heavily pre-treated multiple myeloma and has a list price of $23,900 per month. Its REMS could limit initial uptake, but response rates have been encouraging.
The company has executed $400m worth of deals with smaller governments reflecting a $32-$37 price per dose for the two-shot mRNA-1273 vaccine, but said larger deals will be done at lower prices.